Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Osteosarcoma Market Research Report Information by Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma), Diagnosis & Treatment (Treatment and Diagnosis), End User (Hospitals & Clinics, Diagnostic Centers and Academic & Research Organizations), by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2032

ID: MRFR/MED/3003-CR | 103 Pages | Author: Kinjoll Dey| October 2019

Osteosarcoma Market Overview

The Osteosarcoma Market is projected to reach USD 0.68 Billion by 2032 at 6.1% CAGR during the forecast period 2023-2032.

Osteosarcoma is a common type of bone cancer that is developed in cells that are responsible for the formation of bones. In very rare conditions osteosarcoma occurs in the soft tissue outside the bones. Generally, it mostly occurs in teenagers, young adults, and older adult population.

Osteosarcoma Market

The osteosarcoma market is primarily driven by the high incidence of osteosarcoma, rising expenditure on oncology medicine and research, and the rising demand for new treatments. However, the high cost of treatment and side-effects of chemotherapy are hampering the growth of the market.

Market Dynamics

The Osteosarcoma Market is emerging due to the high incidence of osteosarcoma. For instance, the prevalence of primary bone cancer is increasing across the world. According to the National Institutes of Health (NIH), an estimate of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. According to the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in 2018.

Moreover, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. This cumulative prevalence of osteosarcoma along with the rising geriatric population are driving the osteosarcoma market.

Osteosarcoma Market Revenue, by Type, 2018 (% share)  Osteosarcoma Market

Sources: MRFR Analysis

Osteosarcoma Market Segment

The Osteosarcoma Market has been segmented into type, diagnosis & treatment, end-user, and region.

On the basis of type, the Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. Intramedullary osteosarcoma is estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Usually, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites affected by intramedullary osteosarcoma.

On the basis of diagnosis & treatment, the osteosarcoma market has been segregated into treatment and diagnosis. The treatment segment is further segmented into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment includes limb-sparing surgery and amputation.

The diagnosis segment is further segmented into imaging, biopsies, and blood tests. The imaging segment includes computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others.

On the basis of end-user, the osteosarcoma market has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations. Its hold largest market share can be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, and availability of skilled and qualified professionals.

Osteosarcoma Market Share, by Region, 2018 (%)  Osteosarcoma Market

Sources: MRFR Analysis

Osteosarcoma Market Regional Analysis

The Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas accounted for a market share of 40.02% in 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada.

Europe was the second-largest osteosarcoma market in 2018. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe.

The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market.

The market in the Middle East & Africa is likely to exhibit the lowest growth due to factors such as limited access to and availability of treatment facilities. However, the high prevalence of bone cancer population would support the growth of the market in the region during the forecast period.

Prominent Players

The Prominent Players in the Market Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. The players operating in the osteosarcoma market are focusing on product launches, along with expanding their global footprints by entering untapped markets.    

Osteosarcoma Market Segmentation

Market for Osteosarcoma, by Type

  • Intramedullary Osteosarcoma

  • Juxtacortical Osteosarcoma

  • Extraskeletal Osteosarcoma

Market for Osteosarcoma, by Diagnosis & Treatment

  • Treatment

    • Chemotherapy

    • Cisplatin

    • Doxorubicin

    • Epirubicin

    • Others

      • Surgery

    • Limb-Sparing Surgery

    • Amputation

    • Radiation Therapy

    • Others

  • Diagnosis

    • Imaging

    • Biopsies

      • Needle Biopsy

      • Surgical Biopsy

    • Blood Tests

      • Alkaline Phosphatase Profiling

      • Lactate Dehydrogenase Profiling

      • Others

Market for Osteosarcoma, by End User

  • Hospitals & Clinics

  • Diagnostic Centers

  • Academic & Research Organizations

Market for Osteosarcoma, by Region

  • North America

    • US

    • Canada

  • Latin America

  • Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia & New Zealand

    • Southeast Asia

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Intended Audience

  • Academic research institutes

  • Pharmaceutical companies

  • Biotechnology companies

  • Market research & consulting firms

Report Attribute/Metric Details
Market Size USD 0.68 Billion
Compound Annual Growth Rate (CAGR) 6.1% (2022-2030)
Base Year 2021
Market Forecast Period 2022-2030
Historical Data 2018 & 2020
Market Forecast Units Value (USD million)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Molecule, Indication
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC.
Key Market Opportunities The major companies are rigorously investing in R&D
Key Market Dynamics Growing research and development efforts and increasing awareness about early diagnosis are driving the osteosarcoma market, while challenges in treatment innovation and limited therapeutic options pose significant constraints.

Frequently Asked Questions (FAQ) :

Osteosarcoma Market is projected to grow at a 6.1% CAGR between 2022-2032.

The Americas is expected to dominate the Osteosarcoma Market.

Osteosarcoma Market is predicted to touch USD 0.68 Billion by 2032.

Different end users of the Osteosarcoma Market include diagnostic centers, hospitals and clinics, and academic and research organizations.

Side effects of chemotherapy and high treatment cost may limit the Osteosarcoma Market growth.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.